Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
AssigneesGeneuro SA, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsHervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myound-Hwa Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
Claims4
A method of alleviating or inhibiting the progress of symptoms of sporadic amyotrophic lateral sclerosis (ALS) by neutralizing a HERV-K envelope protein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody that recognizes the HERV-K envelope protein, wherein said antibody comprises a light chain comprising a light chain variable region (VL) which comprises three complementarity determining regions (CDR-L1, CDR-L2 and CDR-L3), and a heavy chain comprising a heavy chain variable region (VH) which comprises three complementarity determining regions (CDR-H1, CDR-H2 and CDR-H3), wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO:1, the CDR-L2 comprises the amino acid sequence of SEQ ID NO:2, the CDR-L3 comprises the amino acid sequence of SEQ ID NO:3, the CDR-H1 comprises the amino acid sequence of SEQ ID NO:4, the CDR-H2 comprises the amino acid sequence of SEQ ID NO:5 and the CDR-H3 comprises the amino acid sequence of SEQ ID NO:6.
Dependencies are inferred from the claim text.